Hepatitis B Virus

Long-term tenofovir treatment in pediatric patients with chronic hepatitis B was well tolerated and correlated with a high rate of viral suppression, according to a study presented at the International Liver Congress.

VIR-2218, an investigational small interfering ribonucleic acid therapeutic, was well tolerated in patients for the treatment of chronic hepatitis B virus, according to research presented at the International Liver Congress.

Treatment with hepatic arterial infusion chemotherapy in combination with sintilimab allowed for surgical resection and produced survival rates similar to lesser advanced hepatocellular carcinoma, according to a presenter at The International Liver Congress.

Tenofovir reduced the severity of COVID-19 infection among patients with chronic hepatitis B, according to a presentation at The Digital International Liver Congress.

May is Hepatitis Awareness Month in the United States, and May 19 is Hepatitis Testing Day.

A one-time, universal screening for chronic hepatitis B infection could prevent 23,000 additional deaths from chronic HBV-related liver disease and save almost $600 million, according to a study in Clinical Infectious Diseases.

Brii Biosciences, Vir Biotechnology and VBI Vaccines announced the first patient dosed in a phase 2 trial evaluating combination therapy for the treatment of patients with chronic hepatitis B infection, according to a press release.

Patients with decompensated cirrhosis due to non-alcoholic steatohepatitis had worse outcomes and more complications than patients with hepatitis B virus, according to study results.

The United States Preventive Services Task Force recently published a new statement strengthening its 2014 recommendation to screen for hepatitis B virus in adolescents and adults who are at an increased risk for infection.

Despite a global initiative to reduce hepatitis B mortality, few of the countries with the highest burden are on track to meet elimination targets, according to research presented at the Liver Meeting Digital Experience.